The UCLA-Boston University Lung Cancer Biomarker Development Laboratory (UCLA-BU BDL) is a multidisciplinary, transiational research program designed to develop and characterize new biomarkers and assays through transiational research in the molecular pathogenesis of lung cancer. By drawing from the vast academic and clinical resources at our two institutions, the UCLA-BU BDL will advance new discoveries and transform them into early detection tools for lung cancer. This discovery-translational continuum is facilitated by a multidisciplinary team of UCLA and BU investigators whose expertise encompasses biological sciences, biostatistics, bioinformatics, translational and clinical pulmonary medicine, pathology and oncology. By joining a seamless collaboration between these investigators, we anticipate that this team will develop biomarkers whose application will disrupt major barriers in early detection and diagnosis of lung cancer.
The aims of our research that will achieve these goals Include: 1) Identify mRNA and microRNA expression profiles in the airways and protein profiles in peripheral blood that can serve as non-invasive diagnostic biomarkers for lung cancer. 2) Develop airway and peripheral blood-based biomarkers capable of preclinical detection of lung cancer among high-risk current and former smokers. 3) Using prospectively collected cohorts, evaluate the classification accuracy of the diagnostic and preclinical detection biomarkers identified in the airway and blood in Alms 1 and 2. We hypothesize that chronic Injury, inflammation and aberrant epithelial repair result in a field of injury that supports lung carcinogenesis and that the molecular, biochemical and cellular events associated with these processes will allow for the detection of early stage lung cancer in non-invasively collected biospecimens, including the mouth, nose and blood. Our proposed studies utilize novel and complementary approaches to solve the clinical problem of early detection of lung cancer in high-risk patients. We are well positioned to perform these studies given: a) the synergy of our groups and institutions which bring together extensive experience in lung cancer chemoprevention and early detection studies;b) our expertise in gene expression profiling and computational biology, c) our access to unique prospective cohorts of high-risk current and former smokers and those with suspect lung cancer in which intra/extra-thoracic airway and blood samples are being collected;d) our preliminary data showing feasibility of the proposed airway and blood biomarker studies as well as the existing collaborations between our investigators and e) the powerful potential of combined multi-compartment, non-invasive testing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA152751-04S1
Application #
8652657
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (M1))
Program Officer
Krueger, Karl E
Project Start
2010-09-24
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
4
Fiscal Year
2013
Total Cost
$781,158
Indirect Cost
$90,948
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Grant, Jeanette L; Fishbein, Michael C; Hong, Long-Sheng et al. (2014) A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis. Cancer Prev Res (Phila) 7:150-60
Ooi, Aik T; Gower, Adam C; Zhang, Kelvin X et al. (2014) Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila) 7:487-95
Liclican, Elvira L; Walser, Tonya C; Hazra, Saswati et al. (2014) Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy. Cancer Prev Res (Phila) 7:845-55
Krysan, Kostyantyn; Kusko, Rebecca; Grogan, Tristan et al. (2014) PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res 12:765-74
Brothers, John F; Hijazi, Kahkeshan; Mascaux, Celine et al. (2013) Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med 11:168
Gomperts, Brigitte N; Walser, Tonya C; Spira, Avrum et al. (2013) Enriching the molecular definition of the airway "field of cancerization:" establishing new paradigms for the patient at risk for lung cancer. Cancer Prev Res (Phila) 6:4-7
Dubinett, Steven M; Spira, Avrum (2013) Challenge and opportunity of targeted lung cancer chemoprevention. J Clin Oncol 31:4169-71
Lee, Gina; Gardner, Brian K; Elashoff, David A et al. (2011) Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients. Am J Transl Res 3:226-33
Beane, Jennifer; Vick, Jessica; Schembri, Frank et al. (2011) Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev Res (Phila) 4:803-17